Everolimus in combination with letrozole inhibit human breast cancer MCF-7/Aro stem cells via PI3K/mTOR pathway: an experimental study

Current Status and Future Perspectives of PI3K and mTOR Inhibitor as Anticancer Drugs in Breast Cancer

(2013) Xiaobei Zhang et al.   CURRENT CANCER DRUG TARGETS

Effects of the combination of RAD001 and docetaxel on breast cancer stem cells

(2012) Xiaobei Zhang et al.   EUROPEAN JOURNAL OF CANCER

Antitumor effect of the mTOR inhibitor everolimus in combination with trastuzumab on human breast cancer stem cells in vitro and in vivo

(2012) Yuanxi Zhu et al.   TUMOR BIOLOGY

The in vitro and in vivo effects of human umbilical cord mesenchymal stem cells on the growth of breast cancer cells

(2011) Yi Ma et al.   BREAST CANCER RESEARCH AND TREATMENT

mTOR inhibition in breast cancer: unraveling the complex mechanisms of mTOR signal transduction and its clinical implications in therapy

(2011) Ruth O'Regan et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Combination of RAD001 and NVP-BEZ235 Exerts Synergistic Anticancer Activity against Non-Small Cell Lung Cancer In Vitro and In Vivo

(2011) Cheng-Xiong Xu et al.   PLoS One

Characterization of AKT independent effects of the synthetic AKT inhibitors SH-5 and SH-6 using an integrated approach combining transcriptomic profiling and signaling pathway perturbations

(2010) Till Krech et al.   BMC CANCER

Low-Molecular-Weight Cyclin E Can Bypass Letrozole-Induced G1 Arrest in Human Breast Cancer Cells and Tumors

(2010) S. Akli et al.   CLINICAL CANCER RESEARCH

Expression of the K303R Estrogen Receptor-  Breast Cancer Mutation Induces Resistance to an Aromatase Inhibitor via Addiction to the PI3K/Akt Kinase Pathway

(2009) I. Barone et al.   CANCER RESEARCH

Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer

(2009) José Baselga et al.   JOURNAL OF CLINICAL ONCOLOGY

Inhibitor hijacking of Akt activation

(2009) Tatsuya Okuzumi et al.   Nature Chemical Biology

Inhibitors of the PI3K/Akt/mTOR Pathway: New Hope for Breast Cancer Patients

(2009) Sandra Ghayad et al.   Recent Patents on Anti-Cancer Drug Discovery

Determinants ofRASistance to Anti–Epidermal Growth Factor Receptor Agents

(2008) José Baselga et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole

(2008) Giuseppe Viale et al.   JOURNAL OF CLINICAL ONCOLOGY